Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 |
| Apr 22, 2024 |
| clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05466175 | A Study of Olverembatinib in the Treatment of Ph+ ALL | unknown | Phase 2 | 55 | Chen SuningOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04334993 | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | unknown | Phase 2 | 110 | Israeli Medical AssociationOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04747093 | Induced-T Cell Like NK Cells for B Cell Malignancies | unknown | Phase 1 / Phase 2 | 12 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03265106 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 20 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04723901 | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04534634 | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL） | unknown | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00199186 | Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | unknown | Phase 2 | — | Johann Wolfgang Goethe University HospitalOTHER | 1 | Oct 19, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2024source: clinicaltrials